Polar Capital’s Ocular Therapeutix OCUL Stock Holding History

Polar Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-57,500	Closed	-$395K	–	264
2016 Q3	$395K	Sell	57,500 -17,373	-23%	-$106K	0.01%	249
2016 Q2	$371K	Buy	74,873 +44,873	+150%	+$445K	0.01%	258
2016 Q1	$290K	Sell	30,000 -5,000	-14%	-$37.9K	0.01%	258
2015 Q4	$328K	Buy	+35,000	New	+$378K	0.01%	258

Other funds holding OCUL

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Polar Capital's OCUL Position: Q4 2016 in Review

Polar Capital sold out of Ocular Therapeutix (OCUL) in Q4 2016, closing a stake of 57,500 shares — an estimated $395K sold.

Polar Capital first reported a position in OCUL in Q4 2015 and held it in 4 quarters. The position peaked at $395K in Q3 2016. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

Polar Capital reported no remaining Ocular Therapeutix position as of Q4 2016 after selling out during the quarter.
Polar Capital sold 57,500 Ocular Therapeutix shares in Q4 2016, an estimated $395K.
Polar Capital first reported a position in Ocular Therapeutix in Q4 2015 and held it in 4 quarters.
Polar Capital's Ocular Therapeutix position peaked at $395K in Q3 2016.
76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on Polar Capital's 13F filing for Q4 2016, filed 14 Feb 2017.